Tags

Type your tag names separated by a space and hit enter

Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate.
J Immunol 2002; 169(5):2231-5JI

Abstract

IFN-tau, a novel type I IFN that possesses immunomodulatory properties, lacks toxicity normally associated with other type I IFNs. We examined the effects of oral IFN-tau alone and in combination with oral glatiramer acetate in experimental allergic encephalomyelitis (EAE). By comparison of oral administration of IFN-alpha, -beta, and -tau to myelin basic protein-specific TCR-transgenic mice, we demonstrate these type I IFNs promote secretion of the Th2 cytokine IL-10 with similar efficiency. Whereas IFN-alpha and -beta induced IFN-gamma secretion, a Th1 cytokine, IFN-tau did not. Oral IFN-tau alone suppressed EAE. When suboptimal doses were administered orally in combination to wild-type mice, IFN-tau and glatiramer acetate had a synergistic beneficial effect in suppression of EAE. This combination was associated with TGF-beta secretion and enhanced IL-10 production. Thus, IFN-tau is a potential candidate for use as a single agent or in combination therapy for multiple sclerosis.

Authors+Show Affiliations

Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12193686

Citation

Soos, Jeanne M., et al. "Cutting Edge: Oral Type I IFN-tau Promotes a Th2 Bias and Enhances Suppression of Autoimmune Encephalomyelitis By Oral Glatiramer Acetate." Journal of Immunology (Baltimore, Md. : 1950), vol. 169, no. 5, 2002, pp. 2231-5.
Soos JM, Stüve O, Youssef S, et al. Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. J Immunol. 2002;169(5):2231-5.
Soos, J. M., Stüve, O., Youssef, S., Bravo, M., Johnson, H. M., Weiner, H. L., & Zamvil, S. S. (2002). Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. Journal of Immunology (Baltimore, Md. : 1950), 169(5), pp. 2231-5.
Soos JM, et al. Cutting Edge: Oral Type I IFN-tau Promotes a Th2 Bias and Enhances Suppression of Autoimmune Encephalomyelitis By Oral Glatiramer Acetate. J Immunol. 2002 Sep 1;169(5):2231-5. PubMed PMID: 12193686.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. AU - Soos,Jeanne M, AU - Stüve,Olaf, AU - Youssef,Sawsan, AU - Bravo,Manuel, AU - Johnson,Howard M, AU - Weiner,Howard L, AU - Zamvil,Scott S, PY - 2002/8/24/pubmed PY - 2002/9/28/medline PY - 2002/8/24/entrez SP - 2231 EP - 5 JF - Journal of immunology (Baltimore, Md. : 1950) JO - J. Immunol. VL - 169 IS - 5 N2 - IFN-tau, a novel type I IFN that possesses immunomodulatory properties, lacks toxicity normally associated with other type I IFNs. We examined the effects of oral IFN-tau alone and in combination with oral glatiramer acetate in experimental allergic encephalomyelitis (EAE). By comparison of oral administration of IFN-alpha, -beta, and -tau to myelin basic protein-specific TCR-transgenic mice, we demonstrate these type I IFNs promote secretion of the Th2 cytokine IL-10 with similar efficiency. Whereas IFN-alpha and -beta induced IFN-gamma secretion, a Th1 cytokine, IFN-tau did not. Oral IFN-tau alone suppressed EAE. When suboptimal doses were administered orally in combination to wild-type mice, IFN-tau and glatiramer acetate had a synergistic beneficial effect in suppression of EAE. This combination was associated with TGF-beta secretion and enhanced IL-10 production. Thus, IFN-tau is a potential candidate for use as a single agent or in combination therapy for multiple sclerosis. SN - 0022-1767 UR - https://www.unboundmedicine.com/medline/citation/12193686/Cutting_edge:_oral_type_I_IFN_tau_promotes_a_Th2_bias_and_enhances_suppression_of_autoimmune_encephalomyelitis_by_oral_glatiramer_acetate_ L2 - http://www.jimmunol.org/cgi/pmidlookup?view=long&pmid=12193686 DB - PRIME DP - Unbound Medicine ER -